Evidence map›Paper›PMID 31714737›Full record

ReviewACS chemical biology2021

End-Binding E3 Ubiquitin Ligases Enable Protease Signaling.

Matthew Ravalin, Koli Basu, Jason E Gestwicki, Charles S Craik

Abstract readReview
In one paragraph

Review in ACS chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. N-degron pathways.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthew RavalinDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94143, United States.ORCID 0000-0003-2998-1933
Koli BasuDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94143, United States.
Jason E GestwickiDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94143, United States.ORCID 0000-0002-6125-3154
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, California 94143, United States.ORCID 0000-0001-7704-9185

Funding

X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FRANKEL, ALAN D · 2007 to 2018
$48.8M
Molecular Chaperones and Small MoleculesR01NS059690 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason E Gestwicki · 2008 to 2026
$7.9M
RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
Renewable antibodies to secreted proteins and single and multi-pass cell surfaceP41CA196276 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2014 to 2018
$5.8M
NCI NIH HHS P41 CA196276NIGMS NIH HHS P50 GM082250NIGMS NIH HHS T32 GM064337NINDS NIH HHS R01 NS059690
6 · The paper itself

Abstract

Post-translational modifications (PTMs) direct the assembly of protein complexes. In this context, proteolysis is a unique PTM because it is irreversible; the hydrolysis of the peptide backbone generates separate fragments bearing a new N and C terminus. Proteolysis can "re-wire" protein-protein interactions (PPIs)

Indexed as

CaspasesHumansProtein BindingProtein Processing, Post-TranslationalProteinsProteolysisSignal TransductionUbiquitinationUbiquitin-Protein LigasesCaspasesProteinsUbiquitin-Protein Ligases

Identifiers

PMID31714737
PMCPMC7400744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.